November 22, 2019
  • November 22, 2019
Breaking News
  • Home
  • Markets
  • Afterhours Laggard: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)

Afterhours Laggard: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)

By on June 24, 2019 0

Technical Stock Analysis

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), a Healthcare sector firm, traded 698237 shares in last trading session and stock plummeted -0.73% with closing price of $134.37 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations, and Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s gross margin stands at 93.80%.

Investment Worthy Stock or not?

For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s profitability or to compare the efficiency of different investments, hence, JAZZ return on investment (ROI) is 12.20%.

52-Week Range

52-Week Range are valuable stats for watching Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s stock value has moved between $113.87 – 184.07 in last one year.

Analyst’s Views

Analysts mean target price for Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) is $172.67 while analysts mean recommendation is 1.90.

Stock Performance

Its weekly performance is 3.02% while year to date (YTD) performance is 8.40%.

EPS Growth

Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s EPS growth this year is 34.60%. For best decision making investors should look at Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ)’s EPS growth for next year stands at 16.59%.


  Markets
Leave a comment